Abeona Therapeutics Inc.
ABEO
$5.74
-$0.12-1.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,745.00% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,745.00% | -- | -- | -- | -- |
| Cost of Revenue | 52.21% | 23.24% | 6.17% | -47.39% | -34.44% |
| Gross Profit | 138.67% | 64.48% | 54.09% | 47.39% | 38.78% |
| SG&A Expenses | -7.66% | 99.28% | 144.62% | 201.59% | 98.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.94% | 60.96% | 69.93% | 56.52% | 29.83% |
| Operating Income | 40.10% | -16.76% | -37.42% | -56.52% | -27.59% |
| Income Before Tax | -116.24% | -41.93% | -122.48% | 32.74% | 1,578.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -118.55% | -41.95% | -120.17% | 82.95% | 1,369.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.55% | -41.95% | -120.17% | 82.95% | 1,369.52% |
| EBIT | 40.10% | -16.76% | -37.42% | -56.52% | -27.59% |
| EBITDA | 41.62% | -16.41% | -36.66% | -57.56% | -28.03% |
| EPS Basic | -117.08% | -24.83% | -94.08% | 84.89% | 1,019.39% |
| Normalized Basic EPS | 33.65% | -24.83% | -96.14% | 40.38% | -388.16% |
| EPS Diluted | -120.75% | -24.83% | -93.27% | 84.13% | 749.79% |
| Normalized Diluted EPS | 15.83% | -24.83% | -96.14% | 40.38% | -390.71% |
| Average Basic Shares Outstanding | 8.61% | 13.75% | 13.43% | 12.81% | 31.28% |
| Average Diluted Shares Outstanding | -14.39% | 13.75% | 13.43% | 12.81% | 30.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |